<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Open Science Publishers LLP</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">197</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"> http://dx.doi.org/10.31782/IJMPS.2022.12503</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>Deep Insights into the Developmental Progress of Orally Disintegrating Tablet Formulation, Techniques, and Products: A Comprehensive Review&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bhakare</surname><given-names>Shweta</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pise</surname><given-names>Ajay G.</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>20</day><month>05</month><year>2022</year></pub-date><volume>)</volume><issue/><fpage>17</fpage><lpage>22</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>When it comes to the design of dosage forms, the ease of medication administration and patient compliance are given significant consideration. Recently developed and emerging technologies may be used to make durable, multifunctional tablets that have exceptional flavor masking properties and controlled release. It is possible to consume orally disintegrating tablets (ODTs) without drinking water since they break down in the mouth in less than 60 seconds and dissolve completely in the mouth. Rapid disintegration of the tablet results in rapid dissolving and, as a result, rapid beginning of action. ODts are a suitable dosage form for special populations such as pediatrics, geriatrics, psychotic patients, patients who are unable to swallow properly, bedridden patients, unconscious patients, young patients with a poorly developed muscular and nervous system, patients who have hand tremors, and patients who travel frequently. Good stability, correct dosage, simplicity of manufacture, and reduced packing size are all advantages; self-administration is allowed throughout the trip since water is not necessary. It is also environmentally friendly. ODTs are a cost-effective technique of delivering medications. When medicine is absorbed via the buccal cavity, oral drug delivery systems (ODTs) are very significant. For the production of ODTs, a variety of scientific procedures have been used, including spray drying, sublimation, freeze-drying, molding, and direct compression. Today, ODTs are more readily accessible as over-the-counter medications for the treatment of a broad range of disorders than they were before. The purpose of this article is to discuss the benefits, limits, formulation issues, manufacturing procedures, patented technologies, and commercially available formulations of ODTs in general.&#13;
</p></abstract><kwd-group><kwd>Oral Disintegrating Tablet</kwd><kwd> Techniques</kwd><kwd> Technology</kwd><kwd> Patent</kwd><kwd> Formulation</kwd><kwd> Challenges</kwd></kwd-group></article-meta></front></article>
